XM2B74ICD-11 MMS 2026-01
Ocrelizumab
Index terms
- Ocrelizumab
Sibling codes
XM0700– OzanimodXM09N4– ImlifidaseXM0V48– UpadacitinibXM1835– TeriflunomideXM1PC0– AnifrolumabXM1PY3– AlefaceptXM1SM6– BaricitinibXM2Q51– Antithymocyte immunoglobulin (rabbit)XM31G3– RavulizumabXM3F23– EmapalumabXM3KK5– EculizumabXM3RJ6– PeficitinibXM3TG8– Antilymphocyte immunoglobulin (horse)XM45M8– AbataceptXM4FP8– BelataceptXM4RN7– AbetimusXM57B1– Mycophenolic acidXM5M04– LeflunomideXM5MC2– VedolizumabXM69Y4– PonesimodXM6N55– SiponimodXM6PD2– SutimlimabXM6QJ6– BelumosudilXM75G0– GusperimusXM76R4– SirolimusXM7BS8– BegelomabXM7U27– TofacitinibXM8913– PegcetacoplanXM8AR9– TeprotumumabXM8CX4– EfalizumabXM93Q8– DeucravacitinibXM9K56– FingolimodXM9M75– BelimumabXM9RY3– Muromonab-CD3XM9UD1– ApremilastXM9YN4– Natalizumab
Foundation entity
Part of: XM5140: Selective immunosuppressants › XM6WT8: Agents primarily affecting blood constituents or immune system › XM6S30: Medicaments › X: Extension Codes